Retatrutide

Retatrutide (LY3437943) is the first triple agonist peptide engaging GLP-1, GIP and glucagon receptors in a single molecule. Phase 3 TRIUMPH-1 topline data (21 May 2026) show mean weight reductions up to 28.3% at 80 weeks, extending to 30.3% at 104 weeks in a high-BMI cohort [18][19]. Research-grade Body Pharm Retatrutide is available through JCSG.org as the Body Pharm Retatrutide 64 Pen.

Key Takeaways

• Retatrutide is a triple-receptor agonist (GLP-1R, GIPR, GCGR) — the most advanced incretin-class peptide in late-stage clinical development
• Phase 2 data show 24.2% mean weight loss at 12 mg weekly (48 weeks); Phase 3 TRIUMPH-1 topline reports up to 30.3% at 104 weeks
• The glucagon receptor component adds energy-expenditure and hepatic-lipolysis pathways absent from approved dual and single agonists
• The Body Pharm Retatrutide 64 Pen is supplied as research-grade reference material with a batch COA
• Realistic licensed UK availability is 2027–2028 at the earliest; until then the compound is investigational

What Is Retatrutide (LY3437943)?

Retatrutide is an investigational synthetic peptide developed by Eli Lilly under the code LY3437943, administered as a once-weekly subcutaneous injection. It is the first molecule to simultaneously activate three incretin and metabolic receptors: GLP-1, GIP, and glucagon. As of mid-2026, it holds no MHRA or EMA marketing authorisation [1][2].

The "Triple G" shorthand, used across UK pharmacy commentary in early 2026, refers to this tri-receptor profile. Each receptor controls a distinct metabolic pathway: GLP-1 receptor (glucose-dependent insulin secretion, satiety signalling), GIP receptor (insulinotropic and adipose-modulating effects), and glucagon receptor (hepatic glucose output and energy expenditure) [1][2]. The Jastreboff et al. NEJM 2023 publication formally describes retatrutide as a "triple-hormone-receptor agonist," with full agonism at GLP-1R and GIPR and a moderated, partial-agonist profile at GCGR to capture thermogenic benefit without driving hyperglycaemia [8].

Structurally, retatrutide is a fatty-acid-modified peptide engineered for albumin binding and weekly dosing. It sits in the same long-acting pharmacokinetic class as the tirzepatide dual agonist peptide and the single-receptor semaglutide GLP-1 peptide, but with a wider receptor footprint. The additional glucagon-receptor component extends the molecule's metabolic reach [8][22].

Current UK Regulatory Status

Retatrutide is not licensed for any indication in the United Kingdom as of June 2026. No MHRA Public Assessment Report exists for LY3437943, and Eli Lilly has not publicly confirmed an EMA validation of application. UK commentary places realistic NHS or private-prescription availability no earlier than 2027–2028, contingent on a US FDA filing expected in Q4 2026 [1][3][13].

Research-grade retatrutide is available for in vitro laboratory use as Body Pharm reference material via the Body Pharm Retatrutide 64 Pen.

Triple vs Dual vs Single Agonist: Receptor Comparison

Retatrutide differs from tirzepatide and semaglutide by engaging a third incretin-family receptor, the glucagon receptor (GCGR), in addition to GLP-1R and GIPR. Tirzepatide acts at GLP-1R and GIPR only. Semaglutide and liraglutide act at GLP-1R alone [9][11].

The mechanistic consequence is an added thermogenic and hepatic-lipolytic axis on top of the appetite-suppressing and insulinotropic effects shared across the class. Glucagon signalling mobilises stored energy independently of the satiety pathways that GLP-1 and GIP engage. Researchers comparing these agents should note that cross-trial efficacy comparisons are confounded by differences in trial duration, baseline BMI, and co-interventions.

Single Agonism: Semaglutide and Liraglutide (GLP-1R)

The semaglutide GLP-1 peptide and liraglutide bind GLP-1R only. They produce glucose-dependent insulin secretion, delayed gastric emptying, and central appetite suppression via hindbrain and hypothalamic GLP-1R populations. Liraglutide is administered daily; semaglutide is once-weekly with a half-life around one week [3]. Both are MHRA-licensed for type 2 diabetes and obesity in the UK as of mid-2026.

Dual Agonism: Tirzepatide (GLP-1R + GIPR)

The tirzepatide dual agonist peptide adds GIP receptor agonism, which potentiates glucose-dependent insulin release and modulates glucagon secretion. GIP acts on receptors in metabolic tissues distinct from GLP-1R, including hypothalamic GIPR populations thought to alter adipocyte lipid handling and central energy balance. Tirzepatide has a terminal half-life of approximately five days, supporting weekly dosing, and is MHRA-authorised as Mounjaro for type 2 diabetes and chronic weight management [3].

Triple Agonism: Retatrutide (GLP-1R + GIPR + GCGR)

Retatrutide retains the GLP-1R/GIPR substrate underlying tirzepatide's efficacy and layers partial agonism at GCGR. Glucagon signalling drives hepatic glucose output, increased resting energy expenditure, and mobilisation of hepatic and visceral lipid stores [9].

Historically, glucagon receptor agonism was avoided as a monotherapy because of hyperglycaemia risk. Co-agonism with GLP-1R is thought to neutralise that risk: insulin secretion stimulated by the GLP-1 arm, combined with glucagonostatic effects on alpha cells, offsets the glycaemic cost of GCGR signalling. The catabolic contribution of GCGR can therefore be expressed as net fat loss rather than worsening glucose control [9].

In Jastreboff et al. (NEJM, 2023), the Phase 2 cohort at 12 mg weekly achieved a mean 24.2% body-weight reduction at 48 weeks versus 2.1% on placebo. Weight loss curves had not yet plateaued at the highest doses at the 48-week observation point [4].

Receptor Comparison Table

Peptide	Receptors Targeted	Administration	UK Approval Status (mid-2026)	Phase of Development
Liraglutide	GLP-1R	Daily SC injection	MHRA-licensed (Saxenda, Victoza)	Marketed
Semaglutide	GLP-1R	Weekly SC; oral form available	MHRA-licensed (Wegovy, Ozempic, Rybelsus)	Marketed
Tirzepatide	GLP-1R + GIPR	Weekly SC injection	MHRA-licensed (Mounjaro, 2023)	Marketed
Retatrutide (LY3437943)	GLP-1R + GIPR + GCGR	Weekly SC injection	Not licensed; investigational only	Phase 3 (TRIUMPH programme); FDA filing planned Q4 2026 [27]

For researchers, retatrutide is the first clinical-stage agent where GCGR partial agonism is deliberately retained. Phase 2 data answered the proof-of-concept question affirmatively at 48 weeks [4]. Phase 3 TRIUMPH-1 topline data (May 2026) extend that signal to 80–104 weeks with up to 30.3% mean weight loss in the high-BMI extension cohort [22].

Why Glucagon Agonism Changes the Equation

GCGR agonism is what separates retatrutide from every previously marketed incretin. It adds a catabolic, energy-expenditure-driven arm to a molecule that otherwise behaves like a more potent tirzepatide dual agonist peptide.

Co-activation with GLP-1R removes the hyperglycaemia liability of isolated GCGR agonism. Insulin secretion stimulated by the GLP-1 arm, combined with glucagonostatic effects on alpha cells, offsets the glycaemic cost of GCGR signalling. The catabolic contribution is expressed as net fat loss rather than worsening glucose control [1]. The GIPR component adds further insulinotropic reserve and appears to modulate adipocyte lipid handling, complementing the GLP-1R-mediated satiety signalling of the semaglutide GLP-1 peptide class.

Phase 2 data are consistent with this model. Jastreboff et al. (NEJM, 2023) reported mean body-weight reductions of 24.2% at 48 weeks on 12 mg weekly versus 2.1% on placebo [1][4]. Hepatic fat reductions in the same cohort exceeded those reported for comparable doses of dual or single agonists [4].

Phase 3 confirmation of the durability and safety of the glucagon contribution is pending peer-reviewed publication. TRIUMPH-1 topline data released 21 May 2026 are consistent with the Phase 2 signal but remain unpublished in full [22].

Retatrutide Clinical Trial Pipeline: UK Status 2026

The retatrutide Phase 3 pipeline is anchored by Eli Lilly's TRIUMPH master protocol programme. TRIUMPH-1 (NCT05929066, protocol J1I-MC-GZBJ) is listed as "Active, not recruiting" on ClinicalTrials.gov as of June 2026, recruitment having closed following the primary completion date of 6 April 2026 [6]. Topline obesity data were released by Lilly on 21 May 2026 [22][26].

J1I-MC-GZBJ is a master protocol with shared eligibility, randomisation and weight-change endpoint, plus nested sub-studies for knee osteoarthritis (J1I-MC-GOA1) and obstructive sleep apnoea (J1I-MC-GSA1) [6].

Named-Trial Pipeline Table (Last Reviewed June 2026)

Trial ID	Phase	Primary Endpoint	Population	UK Sites	Indicative Readout / Status
TRIUMPH-1 / NCT05929066 (J1I-MC-GZBJ)	3	% change in body weight from baseline at Week 72	Adults with obesity/overweight without T2D	Not explicitly flagged on public ClinicalTrials.gov record as of June 2026 [6]	Active, not recruiting; primary completion 6 April 2026; topline 21 May 2026 [6][22]
TRIUMPH-4	3	% change in body weight at Week 68	Obesity cohort	Unconfirmed against ClinicalTrials.gov [unverified]	First pivotal readout reported December 2025: 28.7% mean reduction at 12 mg vs ~2% placebo [15]
Cardiovascular outcomes trial	3	Time-to-event composite MACE	Obesity with established CVD	Not confirmed	Outcome framework registered via Lilly trial portal [16]
NCT04881760 (Jastreboff et al. Phase 2)	2	% weight change at Week 48	Obesity without diabetes	Completed	Published NEJM 2023: 24.2% at 12 mg vs 2.1% placebo [19]

UK-based researchers seeking site-level participation data should cross-reference the NIHR Be Part of Research portal and the EU Clinical Trials Register quarterly, as registry updates lag press communications by weeks to months.

Indicative Regulatory Timeline (Speculative, Source-Dated June 2026)

Lilly's publicly summarised guidance points to an earliest US FDA NDA filing in Q4 2026, with EU and MHRA submissions expected 6–12 months later. This implies a 2027 UK filing window and realistic NHS availability no earlier than 2027–2028 [21][23].

This pipeline table requires quarterly review. Readers comparing retatrutide's pivotal endpoints against the tirzepatide dual agonist peptide SURMOUNT programme or the semaglutide GLP-1 peptide STEP series should treat dose-matched cross-trial comparisons cautiously until full Phase 3 manuscripts are published.

UK Regulatory & Legal Status (Mid-2026)

Retatrutide is not approved by the MHRA or the EMA as of June 2026, and it cannot be lawfully prescribed or dispensed in the UK outside a regulated clinical trial [1][2][3]. No marketing authorisation application has been validated by either regulator, and no MHRA Public Assessment Report exists for LY3437943 [1][3]. Lilly's publicly indicated timeline points to a US FDA filing in Q4 2026 and a UK/EU filing window in 2027 at the earliest [1].

For UK researchers and clinicians, three access categories must be kept strictly separate:

Clinical trial access — only via Eli Lilly-sponsored TRIUMPH protocols registered on ClinicalTrials.gov or the EU CTR, with UK site participation routed through NIHR portfolio adoption where applicable [4][6]. NCT05929066 (TRIUMPH-1) is the principal master protocol, currently active and not recruiting [6].

Research-grade / in vitro supply — UK peptide suppliers may offer LY3437943 reference material for laboratory and analytical use only. Such material is not a medicinal product and carries no MHRA quality assurance. JCSG.org stocks the Body Pharm Retatrutide 64 Pen, supplied as research-use reference material only.

Unlicensed human use — sourcing retatrutide for self-administration or off-label prescribing is not lawful in the UK and is not endorsed here.

MHRA position (June 2026): No licence, no consultation, no horizon-scanning document specific to LY3437943. Obesity-drug safety communications from the MHRA in 2024–2026 continue to focus on licensed agents such as the tirzepatide dual agonist peptide and the semaglutide GLP-1 peptide [1][3].

This status is dated June 2026 and is subject to rapid change once Phase 3 manuscripts publish and Lilly files its regulatory dossiers. Re-verify against the MHRA Products register and ClinicalTrials.gov before relying on any statement above.

Retatrutide as a Research Peptide: In Vitro Applications

Research-grade retatrutide is reference material sold for laboratory use only, distinct from a licensed medicinal product in every regulatory and quality-assurance sense. It is synthesised for in vitro assays without GMP oversight and accompanied by a third-party certificate of analysis. No retatrutide product currently sits in the clinical-grade category anywhere in the world [4][6].

The Body Pharm Retatrutide 64 Pen is supplied through JCSG.org as research-use reference material dispatched to UK laboratory addresses.

Legitimate In Vitro Applications

For laboratories with appropriate ethics and biosafety cover, LY3437943 reference material supports a defined set of experiments: competitive radioligand or fluorescent binding assays at human GLP-1R, GIPR, and GCGR; cyclic adenosine monophosphate (cAMP) accumulation and β-arrestin recruitment assays in HEK293 or CHO lines stably expressing each receptor; comparative dose-response profiling against tirzepatide and semaglutide; and computational or cell-based metabolic pathway modelling interrogating balanced tri-agonism [1][17].

What to Demand from a UK Supplier

Before ordering any research peptide, insist on: batch-specific HPLC trace, mass-spectrometry confirmation, residual solvent data, and an endotoxin result on the COA cross-referenced to the vial batch number. The Body Pharm COA details are listed on the product page.

The current UK price is shown in the buy box on the product page.

Phase 2 Efficacy Data: What the Evidence Shows So Far

Retatrutide produced a mean body-weight reduction of 24.2% at 48 weeks at the 12 mg weekly dose in the Phase 2 obesity trial (NCT04881760). At the time of publication, this was the highest weight loss reported for any incretin-class agent in a randomised obesity study [4].

Jastreboff et al. (NEJM, 2023) reported dose-cohort means of approximately 7.2% (1 mg), 12.9% (4 mg), 17.3% (8 mg), and 24.2% (12 mg), versus 2.1% with placebo, in adults with obesity without type 2 diabetes [4][10]. Weight-loss curves in the 8 mg and 12 mg arms had not plateaued by Week 48 [4].

Mechanistic Comparators from Phase 3 Incretin Trials

For context against approved agents, the tirzepatide dual agonist peptide (SURMOUNT-1, Jastreboff et al., NEJM 2022) achieved up to 22.5% mean body-weight reduction at 72 weeks at the 15 mg dose. The semaglutide GLP-1 peptide (STEP-1, Wilding et al., NEJM 2021) produced a 14.9% mean reduction at 68 weeks at 2.4 mg weekly. Both figures are from primary publications and are quoted here for mechanistic comparison only. Direct cross-trial efficacy comparison is confounded by differences in trial duration, baseline BMI, lifestyle co-intervention, and analysis population.

What Phase 2 Data Does and Does Not Establish

Phase 2 data establishes proof-of-concept efficacy and a dose-response signal sufficient to justify Phase 3 investment. It does not establish regulatory-grade evidence of efficacy, durability beyond 48 weeks, or the cardiovascular and long-term safety profile required for MHRA or EMA marketing authorisation.

Topline Phase 3 TRIUMPH-1 data released by Lilly in May 2026 report mean weight loss up to 28.3% at 80 weeks, but these remain press-release figures pending peer-reviewed publication [15][26][28].

All efficacy figures cited here derive from named clinical trials in supervised dosing protocols. They cannot be extrapolated to research-grade LY3437943 reference material. For research use only — not for human or animal administration.

Structural Genomics Perspective: How Retatrutide Was Designed

Designing a single peptide that simultaneously activates GLP-1R, GIPR, and GCGR with a deliberately unbalanced potency ratio is a structural engineering problem, not a screening one. The three receptors are class B1 G-protein-coupled receptors (GPCRs) sharing a conserved seven-transmembrane fold and an extracellular domain that recognises the C-terminal helix of native ligands.

Retatrutide's published description as a "triple-hormone-receptor agonist" implies a chimeric backbone drawn from GLP-1, GIP, and glucagon motifs, with substitutions chosen to retain full agonism at GLP-1R and GIPR while moderating glucagon receptor activity to a partial-agonist regime [1][2].

Co-crystal and cryo-EM structures of class B1 GPCRs bound to native and analogue peptides allow medicinal chemists to map which residues control receptor selectivity versus efficacy. The role of structural genomics in peptide drug discovery and the broader translation from protein structures to peptide therapeutics describe this workflow in detail, as does our primer on understanding protein-peptide interactions.

Lilly's disclosures also point to a lysine-linked fatty acid side chain conferring albumin binding and a half-life compatible with weekly dosing, a design choice mirrored in tirzepatide and semaglutide [1]. JCSG was not involved in retatrutide's development; the point here is methodological lineage, not attribution.

Frequently Asked Questions